Group 1 - The core point of the article is that Hongyuan Pharmaceutical (301246) announced a profit forecast for 2025, expecting a net profit between 113 million to 137 million yuan, representing a year-on-year growth of 119.57% to 166.20% [2] Group 2 - On January 16, Hongyuan Pharmaceutical's stock closed at 22.57 yuan, up 1.17%, with a turnover rate of 9.58% and a trading volume of 344 million yuan, showing a 2.13% increase over the past five days [2] - Statistics indicate that 68.85% of stocks with a profit forecast increase of over 50% saw their prices rise on the announcement day, with two stocks hitting the daily limit [2] - Over the five days following the announcement, 77.05% of these stocks experienced price increases [2] Group 3 - The stock saw a net inflow of 5.3635 million yuan from main funds today, with a total net inflow of 52.8684 million yuan over the past five days [2] - As of January 15, the margin trading balance was 304 million yuan, with a financing balance of 304 million yuan, reflecting a 9.56% increase from the previous trading day and a cumulative growth of 6.49% over the past five days [2]

Core Viewpoint - Hongyuan Pharmaceutical (301246) expects a significant increase in net profit for the year 2025, projecting a range of approximately 113 million to 137 million yuan, representing a growth of 119.57% to 166.2% compared to the previous year [2] Group 1: Financial Performance - The company anticipates a substantial rise in operating performance for 2025 compared to the same period last year [2] - The expected profit growth is primarily driven by the lithium hexafluorophosphate business [2] Group 2: Market Demand - The demand for new energy vehicles continues to grow, contributing positively to the company's performance [2] - There is a rapid increase in demand within the energy storage market, which has significantly improved the profitability of the lithium hexafluorophosphate business [2]

Core Viewpoint - Hongyuan Pharmaceutical (301246.SZ) expects a significant increase in net profit attributable to shareholders for 2025, projecting between 113 million to 137 million yuan, representing a growth of 119.57% to 166.20% year-on-year [1] Financial Performance - The net profit after deducting non-recurring gains and losses is anticipated to be between 82 million to 106 million yuan, indicating a substantial increase of 782.01% to 1,040.17% compared to the previous year [1] - The expected impact of non-recurring gains and losses on the net profit attributable to shareholders is approximately 31 million yuan [1] Business Drivers - The significant growth in operating performance for 2025 is primarily driven by the lithium hexafluorophosphate business [1] - The demand in the new energy vehicle market and the rapid growth in the energy storage market have notably improved the profitability of the company's lithium hexafluorophosphate business [1]

智通财经APP讯，宏源药业(301246.SZ)发布2025年度业绩预告，预计全年实现归属于上市公司股东的净 利润1.13亿元至1.37亿元，同比增长119.57%-166.20%。 2025年度经营业绩预计较去年同期大幅上升，主要受六氟磷酸锂业务影响。报告期内，新能源车市场需 求持续增长以及储能市场需求快速增长，公司六氟磷酸锂业务盈利能力显著改善。 ...

2025年度经营业绩预计较去年同期大幅上升，主要受六氟磷酸锂业务影响。报告期内，新能源车市场需 求持续增长以及储能市场需求快速增长，公司六氟磷酸锂业务盈利能力显著改善。 宏源药业（301246）(301246.SZ)发布2025年度业绩预告，预计全年实现归属于上市公司股东的净利润 1.13亿元至1.37亿元，同比增长119.57%-166.20%。 ...

Core Viewpoint - Hongyuan Pharmaceutical (301246) expects a significant increase in net profit for 2025, projecting a range of 113 million to 137 million yuan, representing a year-on-year growth of 119.57% to 166.2% [1] Group 1 - The demand for new energy vehicles continues to grow, contributing positively to the company's performance [1] - The energy storage market is experiencing rapid growth, further enhancing the profitability of the company's lithium hexafluorophosphate business [1]

Core Viewpoint - Hongyuan Pharmaceutical expects a significant increase in net profit for the fiscal year 2025, driven primarily by its lithium hexafluorophosphate business, which has seen improved profitability due to rising demand in the new energy vehicle and energy storage markets [1] Financial Performance - The projected net profit for 2025 is estimated to be between 113 million to 137 million yuan, representing a year-on-year growth of 119.57% to 166.20% [1] - The net profit after deducting non-recurring gains and losses is expected to be between 82 million to 106 million yuan, showing a substantial year-on-year increase of 782.01% to 1,040.17% [1] - The impact of non-recurring gains and losses on the net profit attributable to shareholders of the listed company is estimated to be approximately 31 million yuan [1] Business Drivers - The significant growth in the company's operating performance is mainly attributed to the lithium hexafluorophosphate business [1] - Continuous growth in demand for new energy vehicles and rapid expansion in the energy storage market have contributed to the notable improvement in profitability [1]

证券代码：301246 证券简称：宏源药业 公告编号：2026-001 湖北省宏源药业科技股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日 2、业绩预告情况：预计净利润为正值且属于同向上升 50%以上情形 单位：万元 本次业绩预告相关数据是公司财务部门初步测算的结果，未经会计师事务所审计。但 公司已就业绩预告有关事项与年报审计会计师事务所进行了预沟通，公司与会计师事务所 在本报告期的业绩预告方面不存在重大分歧，具体数据以审计结果为准。 三、业绩变动原因说明 2025 年度经营业绩预计较去年同期大幅上升，主要受六氟磷酸锂业务影响。报告期 内，新能源车市场需求持续增长以及储能市场需求快速增长，公司六氟磷酸锂业务盈利能 力显著改善。 预计报告期内非经常性损益对归属于上市公司股东的净利润的影响金额约为 3,100 万 元。 四、其他相关说明 本次业绩预告相关财务数据是公司财务部门初步测算的结果，未经审计机构审计，具 体财务数据公 ...

证券日报网讯 1月14日，宏源药业在互动平台回答投资者提问时表示，公司密切关注各产品市场变动情 况，并及时调整营销策略。公司境内、外具体营销情况请关注公司后续定期报告。 （文章来源：证券日报） ...

Core Viewpoint - Hongyuan Pharmaceutical (301246.SZ) is currently experiencing a decline in stock price, closing at 22.28 yuan with a drop of 2.28%, indicating a state of being below its initial public offering (IPO) price [1]. Group 1: IPO Details - Hongyuan Pharmaceutical was listed on the Shenzhen Stock Exchange's ChiNext board on March 20, 2023, with a public offering of 47.2572 million shares at an issuance price of 50.00 yuan per share [1]. - On its first trading day, the stock reached a peak price of 45 yuan, which remains the highest price since its listing [1]. - The total amount raised from the IPO was 2.36286 billion yuan, with a net amount of 2.19584 billion yuan after deducting issuance costs, exceeding the original plan by 1.54511 billion yuan [1]. Group 2: Fund Utilization - The company planned to use the raised funds of 650.73 million yuan for projects including a research and development center, a multifunctional testing workshop, and a high-end formulation workshop with an annual production capacity of 2.5 billion tablets (or granules) [1]. Group 3: Issuance Costs - The total issuance costs for the IPO amounted to 167.0163 million yuan, with underwriting and sponsorship fees accounting for 139.3196 million yuan [1].